BOULDER, Colo., Oct. 3, 2016 /PRNewswire/ -- Array BioPharma
Inc. (NasdaqGM: ARRY) announced today the closing of its
underwritten public offering of 21,160,000 shares of its common
stock, which includes 2,760,000 shares of common stock issued upon
the exercise in full of the option to purchase additional shares
granted to the underwriters, at a public offering price
of $6.25 per share. The total gross proceeds from the
offering are $132.25 million, before underwriting discounts
and commissions and offering expenses.
J.P. Morgan Securities LLC and Cowen and Company, LLC acted
as joint book-running managers for the offering. Stifel and
Wells Fargo Securities, LLC acted as lead managers and SunTrust
Robinson Humphrey, Inc. acted as co-manager.
The shares were sold pursuant to an effective shelf registration
statement filed with the Securities and Exchange
Commission (the "SEC"). This press release does not constitute
an offer to sell, or the solicitation of an offer to buy, these
securities, nor will there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale is not permitted.
A final prospectus supplement relating to the offering was filed
with the SEC and is available on the SEC's web site
at www.sec.gov. Copies of the final prospectus supplement and
accompanying prospectus may be obtained from either: J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New
York 11717, telephone: 866-803-9204, or Cowen and Company,
LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, New York, 11717, Attn:
Prospectus Department, telephone: 631-274-2806.
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Five registration studies are
currently advancing related to three cancer drugs. These programs
include binimetinib (MEK162), encorafenib (LGX818) and selumetinib
(AstraZeneca).
CONTACTS:
|
Tricia
Haugeto
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
Logo -
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-300337934.html
SOURCE Array BioPharma